Eli Lilly and Company (LLY) Tuesday reported positive topline results from the Phase 3 BRUIN CLL-314 study evaluating pirtobrutinib versus ibrutinibin in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). The study met its primary goal of non-inferiority on overall response rate (ORR).
The overall safety profile of pirtobrutinib in the study was consistent with previously reported studies.
"The BRUIN CLL-313 Phase 3 study of pirtobrutinib versus chemoimmunotherapy in treatment naïve CLL/SLL is expected to read out later in 2025 and combined with the results of BRUIN CLL-314, will form the basis of regulatory submissions globally," the company said in a statement.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.